|
Peter French, MBA, PhD, is a cell and molecular biologist who has extensive experience in both basic and clinical medical research and commercialisation of biological intellectual property. His research areas of expertise include cell biology, immunology, infectious disease (including HIV/AIDS), neurobiology and oncology. He obtained his PhD in 1987 for work performed at CSIRO elucidating the molecular composition of keratin proteins in the developing wool follicle. He carried out postdoctoral research on neuronal development at the Children's Medical Research Foundation, Sydney. He was Principal Scientific Officer and Manager of the Centre for Immunology, St Vincent's Hospital Sydney, from 1987 to 2002. He gained an MBA in Technology Management in 2000. |
|
Mr West is a Chartered Accountant with experience in the Biotech sector. He is a Director and audit committee Chairman of ITC Limited (a business arm of Wollongong University), IDP Education Pty Ltd and Education Australia Limited. He completed his studies with Price Waterhouse and has worked in senior finance executive roles in investment banking with Bankers Trust, Deutsche Bank, NZI, and other financial institutions. |
|
Mr Stubbings is a highly qualified senior executive with over thirty years experience in biotechnology and medical diagnostics. His background includes manufacturing, administration, and extensive international sales and marketing expertise in North America, Latin America, Asia Pacific and Europe. Prior to joining Benitec Carl was Vice President of Sales & Marketing for Focus Diagnostics a subsidiary of Quest Diagnostics (NASDAQ DGX), one of world’s largest pathology provider. Prior to moving back to Australia, Carl and his family had lived and worked in the USA for more than 12 years. In December 2011 Carl was appointed as a non-executive director of Sienna Diagnostics (a public unlisted company). Carl Stubbings holds a B.Sc. degree from the Queensland University of Technology; he holds dual Australian and US citizenship. |
|
Dr Graham’s research interests are in the field of molecular genetics, with a particular focus on the applications of RNAi in biotechnology. He commenced the development of Benitec’s ddRNAi technology while working in plant biotechnology at CSIRO and continued this work at QDPI and Benitec, focusing on medical applications; the core Benitec patent portfolio was developed at this time. Following Benitec’s restructure Dr Graham moved to the University of Queensland where he worked on developing applications of RNAi in plant biotechnology in an industry collaborative program. In January 2012 Dr Graham re-joined Benitec Biopharma as Chief Scientist and oversees the development of Benitec Biopharma’s scientific programs.
|
